YU91403A - Antitela specifična za cd44v6 - Google Patents

Antitela specifična za cd44v6

Info

Publication number
YU91403A
YU91403A YU91403A YUP91403A YU91403A YU 91403 A YU91403 A YU 91403A YU 91403 A YU91403 A YU 91403A YU P91403 A YUP91403 A YU P91403A YU 91403 A YU91403 A YU 91403A
Authority
YU
Yugoslavia
Prior art keywords
antibody
antibody proteins
cd44v6
antibodies specific
antibodies
Prior art date
Application number
YU91403A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Gunther Adolf
Elinborg Ostermann
Erik Patzelt
Marlies Sproll
Karl-Heinz Heider
John J. Miglietta
Augustinus A.M.S. Van Dongen
Original Assignee
Boehringer Ingelheim International Gmbh.
Boehringer Ingelheim Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh., Boehringer Ingelheim Pharmaceuticals Inc. filed Critical Boehringer Ingelheim International Gmbh.
Publication of YU91403A publication Critical patent/YU91403A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
YU91403A 2001-05-18 2002-05-17 Antitela specifična za cd44v6 YU91403A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01112237 2001-05-18
US32514701P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
YU91403A true YU91403A (sh) 2006-05-25

Family

ID=33442672

Family Applications (1)

Application Number Title Priority Date Filing Date
YU91403A YU91403A (sh) 2001-05-18 2002-05-17 Antitela specifična za cd44v6

Country Status (18)

Country Link
EP (1) EP1397387A1 (https=)
JP (1) JP2005504517A (https=)
CN (1) CN1541226A (https=)
AR (1) AR036154A1 (https=)
BR (1) BR0210905A (https=)
CA (1) CA2443437A1 (https=)
CZ (1) CZ20033476A3 (https=)
EA (1) EA200301169A1 (https=)
EC (1) ECSP034838A (https=)
EE (1) EE200300569A (https=)
HU (1) HUP0400030A3 (https=)
MX (1) MXPA03010523A (https=)
PE (1) PE20021098A1 (https=)
PL (1) PL365735A1 (https=)
SK (1) SK15592003A3 (https=)
WO (1) WO2002094879A1 (https=)
YU (1) YU91403A (https=)
ZA (1) ZA200307365B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
CA2600505C (en) 2005-03-10 2016-05-03 Morphotek, Inc. Anti-mesothelin antibodies
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
SG182191A1 (en) * 2007-06-13 2012-07-30 Zymogenetics Inc Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
SI2531527T1 (sl) 2010-02-04 2014-07-31 F. Hoffmann-La Roche Ag Monoklonsko protitelo proti CD44 za uporabo pri zdravljenju skvamoznoceličnega karcinoma glave in vratu
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
WO2017215637A1 (zh) * 2016-06-15 2017-12-21 李翀 一种人子宫内膜癌的标志物、抗体及其应用
CN107556388A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用
EP4114860A1 (en) * 2020-03-06 2023-01-11 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
EP4301782A1 (en) * 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
JPH08506801A (ja) * 1992-11-20 1996-07-23 アイシス・イノベーション・リミテッド Ｃｄ４４エキソン６に対応するペプチド、そのペプチドに特異的な抗体、および、腫瘍診断にそれらの抗体を使用する方法
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano

Also Published As

Publication number Publication date
CN1541226A (zh) 2004-10-27
WO2002094879A1 (en) 2002-11-28
CZ20033476A3 (cs) 2004-05-12
PL365735A1 (en) 2005-01-10
PE20021098A1 (es) 2003-02-11
EA200301169A1 (ru) 2004-06-24
HUP0400030A3 (en) 2006-02-28
ECSP034838A (es) 2003-12-24
EE200300569A (et) 2004-04-15
CA2443437A1 (en) 2002-11-28
BR0210905A (pt) 2004-06-08
JP2005504517A (ja) 2005-02-17
HUP0400030A2 (hu) 2004-04-28
MXPA03010523A (es) 2004-07-01
ZA200307365B (en) 2004-05-10
AR036154A1 (es) 2004-08-18
EP1397387A1 (en) 2004-03-17
SK15592003A3 (sk) 2004-06-08

Similar Documents

Publication Publication Date Title
YU91403A (sh) Antitela specifična za cd44v6
EP3660510A3 (en) Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
CY1122476T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (τfρι)
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
EA200800229A1 (ru) Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1)
EA200900424A1 (ru) Человеческие антитела, которые связываются с cxcr4, и их применение
UA101301C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ
WO2002083171A3 (en) Cancer treatment by using fap-alpha specific antibodies
BRPI0716997A8 (pt) sistema ou composição de molécula protéica, método para produção da dita composição, bem como método para selecionar célula hospedeira para produzir a dita composição, uso de célula sanguínea humana imortalizada e ácido nucléico
DK1633784T3 (da) OVR110 antistofsammensætninger og -anvendelsesfremgangsmåder
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1
HRP20080028A2 (en) Cd19 antibodies and their uses
DE602004030811D1 (de) Multispezifische deimmunisierte cd3-bindende moleküle
BR0307837A (pt) Anticorpos anti-abeta e seu uso
MX2009005776A (es) Anticuerpos humanos que se enlazan al cd 22 y sus usos.
WO2007067991A3 (en) Human monoclonal antibodies to o8e
MX2010008570A (es) Anticuerpos alfa5-beta1 y sus usos.
WO2006076691A3 (en) Irta-2 antibodies and their uses
WO2005097185A3 (en) Irta-5 antibodies and their uses
ATE462726T1 (de) Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
ATE514718T1 (de) Peptabody für krebsbehandlung
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
Citarella et al. Discovery of a novel trifluoromethyl diazirine inhibitor of SARS-CoV-2 Mpro